PT Kimia Farma (Persero) Tbk reported an improvement in its financial performance through the third quarter of 2026, maintaining sales at IDR 7 trillion while recording a 129.31% increase in operating profit and a 32.04% rise in EBITDA year-on-year (YoY) (02/11).

The company's operating profit reached IDR 227 billion, compared with IDR 99 billion in the same period of 2025. EBITDA also increased to IDR 503 billion from IDR 381 billion in the third quarter of the previous year.

Meanwhile, Kimia Farma reduced its net loss to IDR 13 billion, compared with IDR 234 billion in the third quarter of 2025. This represented an improvement of IDR 221 billion, or approximately 94.49%.

Kimia Farma Q3 2026 Financial Performance Shows Improvement

The improvements reflect the company's ongoing business and financial transformation, particularly through stronger operational performance, increased efficiency, and better resource management.

Djagad Prakasa Dwialam, President Director of PT Kimia Farma (Persero) Tbk, said the company's financial results demonstrated positive progress in its transformation process.

“The Company’s performance through the third quarter of 2026 shows that the turnaround process is progressing in a positive direction. The 129.31% growth in operating profit and 32.04% growth in EBITDA reflect improvements in the fundamentals of our operational performance, as well as the results of ongoing efforts to enhance business efficiency and effectiveness. We will continue to maintain this momentum by strengthening our business fundamentals and ensuring that every step of the transformation delivers a tangible impact on the Company’s sustainability,” said Djagad.

He added that reducing the company's net loss was another important development in its transformation journey.

“This reduction in net loss marks a significant development in Kimia Farma’s transformation journey. Our focus extends beyond short-term financial improvements; we are building a healthier business foundation, strengthening operational discipline, and enhancing the company’s competitiveness to ensure sustainable growth,” added Djagad.

Six Transformation Pillars Support Kimia Farma's Business Recovery

Kimia Farma continues to implement a transformation strategy based on six key pillars to maintain its business and financial improvements. These pillars consist of working capital resilience, human resource (HR) competency development, business process digitalization, operational efficiency, Good Corporate Governance (GCG), and synergy across the Kimia Farma Group.

In financial management, the company is strengthening working capital and liquidity management to support more effective operational activities.

Operational improvements focus on cost control, optimized asset utilization, and better product portfolio management. The company is also aligning its product offerings with market needs and their contributions to overall business performance.

Meanwhile, digitalization, employee competency development, and stronger corporate governance remain important parts of the transformation. These efforts are intended to build an organization that is more adaptive, productive, and accountable.

Kimia Farma is also encouraging greater synergy across its business group to optimize existing capabilities, improve coordination, and create added value for the company.

Kimia Farma Focuses on Financial Management and Corporate Governance

Entering the fourth quarter of 2026, Kimia Farma continues to prioritize corporate governance transformation and stronger business fundamentals.

The company's efforts include strengthening internal controls, risk management, disciplined decision-making, and accountability to support healthier and more sustainable corporate management.

In its business and financial operations, Kimia Farma is continuing to improve working capital and liquidity management, cost control, asset productivity, and product portfolio optimization.

These measures are directed at improving operational efficiency and performance quality while strengthening the company's competitiveness and business foundation.

The company is also continuing to address historical challenges through a careful and measured approach, in accordance with applicable regulations and good corporate governance principles.

These matters are being handled while considering the interests of the company and its shareholders, as well as the sustainability of its operations.

Kimia Farma Strengthens Its Role in National Health Resilience

As part of the Bio Farma Group within the Danantara Indonesia ecosystem, Kimia Farma plays a strategic role in supporting national health resilience.

The company continues to strengthen business synergies and supply chains to improve efficiency and support the availability of healthcare products and services.

Its transformation is also aimed at building a more resilient business, strengthening its contribution to the self-reliance of Indonesia's pharmaceutical industry, and supporting national health resilience.

PHOTO: KIMIA FARMA

This article was created with AI assistance.

We make every effort to ensure the accuracy of our content, some information may be incorrect or outdated. Please let us know of any corrections at [email protected].